RESEARCHER PROFILE

Scott J. Rodig

← Back to Harvard University

S

Harvard University

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research StudiesLymphoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Scott J. Rodig works in Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lymphoma Diagnosis and Treatment, Cancer Genomics and Diagnostics. Recorded institutional associations include Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute.

1,578Publications
78,060Citations
130H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

    2014 · 3,560 citations
  2. An immunogenic personal neoantigen vaccine for patients with melanoma

    2017 · 2,917 citations
  3. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy

    2016 · 2,451 citations
  4. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

    2019 · 2,063 citations
  5. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

    2018 · 1,935 citations
  6. Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    2009 · 1,870 citations
  7. Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway

    1996 · 1,657 citations
  8. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

    2016 · 1,577 citations
  9. Adaptive immunity maintains occult cancer in an equilibrium state

    2007 · 1,436 citations
  10. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

    2018 · 1,425 citations
  11. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

    2010 · 1,305 citations
  12. MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

    2012 · 1,294 citations
  13. Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

    2013 · 1,231 citations
  14. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

    2016 · 1,001 citations
  15. Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia

    2015 · 942 citations
  16. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    2016 · 927 citations
  17. Crizotinib in ALK -Rearranged Inflammatory Myofibroblastic Tumor

    2010 · 870 citations
  18. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

    2019 · 869 citations
  19. Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses

    1998 · 853 citations
  20. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

    2013 · 843 citations
  21. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

    2016 · 791 citations
  22. Tet1 and Tet2 Regulate 5-Hydroxymethylcytosine Production and Cell Lineage Specification in Mouse Embryonic Stem Cells

    2011 · 775 citations
  23. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    2013 · 733 citations
  24. Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

    2012 · 685 citations
  25. Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

    2015 · 684 citations

← Return to the university profile